Home  »  Industry   »  A peek at Paratek Pharmaceuticals Inc. (PRTK): Who...

A peek at Paratek Pharmaceuticals Inc. (PRTK): Who has invested in It?

Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) is -50.56% lower on its value in year-to-date trading and has touched a low of $1.60 and a high of $4.95 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PRTK stock was last observed hovering at around $2.13 in the last trading session, with the day’s gains setting it 0.09% off its average median price target of $20.00 for the next 12 months. It is also 92.6% off the consensus price target high of $30.00 offered by 3 analysts, but current levels are 79.82% higher than the price target low of $11.00 for the same period.

Currently trading at $2.22, the stock is -14.89% and -19.01% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.27 million and changing 4.23% at the moment leaves the stock -15.84% off its SMA200. PRTK registered -50.99% loss for a year compared to 6-month gain of 27.59%.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


The stock witnessed a -37.46% loss in the last 1 month and extending the period to 3 months gives it a -18.98%, and is 8.29% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.65% over the week and 7.88% over the month.

Paratek Pharmaceuticals Inc. (PRTK) has around 207 employees, a market worth around $124.63M and $116.50M in sales. Fwd P/E is 6.34. Profit margin for the company is -76.10%. Distance from 52-week low is 38.75% and -55.15% from its 52-week high. The company has generated returns on investments over the last 12 months (-33.00%).

Paratek Pharmaceuticals Inc. (PRTK) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Paratek Pharmaceuticals Inc. (PRTK) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.30, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Paratek Pharmaceuticals Inc. is expected to release its quarterly report on 03/02/2023.The EPS is expected to grow by 44.20% this year

Paratek Pharmaceuticals Inc. (PRTK) Top Institutional Holders

The shares outstanding are 55.17M, and float is at 46.32M with Short Float at 7.01%.

Paratek Pharmaceuticals Inc. (PRTK) Insider Activity

A total of 19 insider transactions have happened at Paratek Pharmaceuticals Inc. (PRTK) in the last six months, with sales accounting for 9 and purchases happening 10 times. The most recent transaction is an insider sale by Woodrow Adam, the company’s President & Chief Commercial. SEC filings show that Woodrow Adam sold 4,563 shares of the company’s common stock on Oct 28 at a price of $3.47 per share for a total of $15834.0. Following the sale, the insider now owns 0.65 million shares.

Paratek Pharmaceuticals Inc. disclosed in a document filed with the SEC on Oct 28 that Loh Evan (CEO) sold a total of 8,805 shares of the company’s common stock. The trade occurred on Oct 28 and was made at $3.47 per share for $30553.0. Following the transaction, the insider now directly holds 1.28 million shares of the PRTK stock.

Still, SEC filings show that on Oct 28, Haskel William M. (CLO, General Counsel & Sec.) disposed off 4,382 shares at an average price of $3.47 for $15206.0. The insider now directly holds 437,801 shares of Paratek Pharmaceuticals Inc. (PRTK).

Paratek Pharmaceuticals Inc. (PRTK): Who are the competitors?

The company’s main competitors (and peers) include Vanda Pharmaceuticals Inc. (VNDA) that is trading -40.73% down over the past 12 months and Neurocrine Biosciences Inc. (NBIX) that is 36.62% higher over the same period. Jazz Pharmaceuticals plc (JAZZ) is 16.76% up on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.